Oct
2026
Fiera Milano, Italy
Visit us
stand 8L58, Contract Manufacturing & Services

TBD Pharmatech

Exhibitor at CPHI Milan 2026
About Us

TBD Pharmatech is an Estonian–Dutch CDMO specializing in small-molecule APIs for human and veterinary use.

With two EU GMP-certified sites in Tartu, we provide end-to-end services from route scouting and tech transfer to clinical and commercial manufacturing, analytics, and regulatory support.

Since 2006 we’ve developed 30+ APIs and supported 10+ ASMF/DMFs, standing out through agility, dual-sector expertise, and global compliance to deliver tailored, high-quality solutions worldwide.

  • Country/Region:
    Estonia
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    50 - 99
Company types
CMO/CDMO
Primary activities
Analytical Services
Animal Health
API Producer
Chemical Development
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Excipients Manufacturer
Generic APIs producer
Intermediates Manufacturer
Contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 8L58, Contract Manufacturing & Services

Products Featured at CPHI Milan 2026

  • Bortezomib

    Product Bortezomib

    Bortezomib is a targeted anticancer drug classified as a proteasome inhibitor, primarily used in the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting the 26S proteasome, a protein complex responsible for degrading unneeded or damaged proteins within cells. By blocking this sys...
  • Butorphanol tartrate

    Product Butorphanol tartrate

    Butorphanol tartrate is a synthetic opioid analgesic and is used for the management of moderate to severe pain, as well as for sedation in certain medical procedures.

    It is commonly used in both human and veterinary medicine. In veterinary medicine, it’s often used for pre-anesthetic medicat...
  • Pomalidomide

    Product Pomalidomide

    Pomalidomide is an oral immunomodulatory drug (IMiD) primarily used in the treatment of relapsed or refractory multiple myeloma, particularly in patients who have already received other therapies such as lenalidomide and bortezomib. Structurally related to thalidomide, pomalidomide works by modulating the ...

TBD Pharmatech Resources (1)